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Pulmonary fibrosis is pathologic remodeling of lung tissue that can result in difficulty
breathing, reduced quality of life, and a poor prognosis for patients. Fibrosis occurs
as a result of insult to lung tissue, though mechanisms of this response are not
well-characterized. The disease is driven in part by dysregulation of fibroblast proliferation
and differentiation into myofibroblast cells, as well as pro-fibrotic mediator-driven
epithelial cell apoptosis. The most well-characterized pro-fibrotic mediator associated
with pulmonary fibrosis is TGF-β1. Excessive synthesis of, and sensitivity to, pro-fibrotic
mediators as well as insufficient production of and sensitivity to anti-fibrotic mediators has
been credited with enabling fibroblast accumulation. Available treatments neither halt nor
reverse lung damage. In this study we have two aims: to identify molecular and cellular
scale mechanisms driving fibroblast proliferation and differentiation as well as epithelial
cell survival in the context of fibrosis, and to predict therapeutic targets and strategies.
We combine in vitro studies with a multi-scale hybrid agent-based computational
model that describes fibroblasts and epithelial cells in co-culture. Within this model
TGF-β1 represents a pro-fibrotic mediator and we include detailed dynamics of TGF-β1
receptor ligand signaling in fibroblasts. PGE2 represents an anti-fibrotic mediator. Using
uncertainty and sensitivity analysis we identify TGF-β1 synthesis, TGF-β1 activation, and
PGE2 synthesis among the keymechanisms contributing to fibrotic outcomes.We further
demonstrate that intervention strategies combining potential therapeutics targeting both
fibroblast regulation and epithelial cell survival can promote healthy tissue repair better
than individual strategies. Combinations of existing drugs and compounds may provide
significant improvements to the current standard of care for pulmonary fibrosis. Thus, a
two-hit therapeutic intervention strategy may prove necessary to halt and reverse disease
dynamics.
Keywords: pulmonary fibrosis, transforming growth factor beta1, fibroblasts, epithelial cells, agent-based
modeling, prostaglandin E2, IPF, therapeutics for fibrosis
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INTRODUCTION
Pulmonary fibrosis is a pathologic feature associated with many
interstitial lung diseases (Buzan and Pop, 2015). A wide range
of lung insults can result in development of fibrosis, including
antibiotic treatment, infection, and environmental exposures
(Vanhee et al., 1994; Daba et al., 2004; Wootton et al., 2011; Zhou
et al., 2015). In cases described as idiopathic pulmonary fibrosis
(IPF), no explicit cause of fibrosis can be identified (Raghu
et al., 2006). Disease presentation includes stiffening and scarring
of lungs, decreased flexibility of tissues, and diminished gas
exchange (Selman et al., 2004; Swigris et al., 2005; Tzanakis et al.,
2005; Maher et al., 2007; Tomioka et al., 2007; Taniguchi et al.,
2011). Patients suffering from pulmonary fibrosis have difficulty
breathing, reduced quality of life, and ultimately a poor prognosis
(De Vries et al., 2001; Jastrzebski et al., 2005; Nishiyama et al.,
2005; Swigris et al., 2005; Tzanakis et al., 2005; Tomioka et al.,
2007; Zimmermann et al., 2007; Raghu et al., 2010; Verma et al.,
2011).
Although mechanisms leading to pulmonary fibrosis are
not well-characterized, it is believed that pulmonary fibrosis
occurs as the result of dysregulation during the wound healing
process (Witte and Barbul, 1997; Diegelmann and Evans, 2004;
Strieter, 2008; Hinz et al., 2012). Wound healing occurs in four
stages: (I) coagulation and hemostasis, (II) inflammation, (III)
proliferation, and (IV) remodeling (Selman et al., 2004). During
the third stage of wound healing, fibroblasts proliferate into
the wound gap (Midwood et al., 2004). They secrete cytokines,
including transforming growth factor-β (TGF-β), which act in
both an autocrine and paracrine manner to induce further
proliferation and/or eventual differentiation of fibroblasts into
myofibroblasts (Desmouliere et al., 1993; Kolodsick et al., 2003;
Thannickal et al., 2003; Epa et al., 2015). Myofibroblasts play
an important role in the fourth stage of the wound healing
process, the remodeling stage. They secrete extracellular matrix
(ECM) proteins including collagen and fibronectin (Witte and
Barbul, 1997; Midwood et al., 2004; Velnar et al., 2009) that
are cross-linked to provide a substrate for re-epithelialization
of wounded tissue (Midwood et al., 2004). Myofibroblasts
also express α-smooth muscle actin (αSMA), a protein that
integrates into actin filaments giving cells a contractile phenotype
(Desmouliere et al., 1993; Hinz et al., 2001; Peyton et al., 2008).
Through integrin binding, myofibroblasts are able to adhere
to surrounding tissue and contract, collapsing the wound gap
(Thannickal et al., 2003; Ibrahim et al., 2015). Dysregulation of
this process, through unknown mechanisms, results in excessive
ECM protein secretion and tissue remodeling. These actions
result in the formation of stiff, scarred tissue that is inflexible, and
unproductive for gas exchange (Selman et al., 2004; Jastrzebski
et al., 2005).
In addition to fibroblasts and myofibroblasts, epithelial cells
are a critical component of effective pulmonary wound healing
(Camelo et al., 2014). Epithelial cell damage is congruent with
pulmonary fibrosis (Adamson and Bowden, 1974; Lama et al.,
2002; Maher et al., 2010; Camelo et al., 2014; Prasad et al.,
2014). Epithelial cells are an essential component of properly
functioning lung tissue. They line the bronchi, airways, and
alveoli of the lungs providing a surface for gas exchange and a
barrier for infectious agents (Mayer and Dalpke, 2007; Crystal
et al., 2008; Holtzman et al., 2014). During pulmonary injury,
epithelial cells are damaged and repair is needed in order to
restore functionality to the wounded tissue (Adamson, 1984;
Prasad et al., 2014; Epa et al., 2015). During fibrosis, excessive
secretion of pro-fibrotic cytokines such as TGF-β1 produces an
environment that is toxic to epithelial cells (Willis and Borok,
2007; Crosby and Waters, 2010). Furthermore, excessive tissue
remodeling can induce further epithelial cell damage, loss of
epithelial protective factors and tissue contraction reducing the
surface area available for re-epithelialization (Krieg et al., 2007;
Hinz et al., 2012).
At the apex of cell-cell interactions during pulmonary wound
healing are two key classes of cytokines: pro-fibrotic mediators
and anti-fibrotic mediators. TGF-β1, the most well characterized
pro-fibrotic mediator in pulmonary fibrosis, is a cytokine
secreted by a wide range of cell types including fibroblasts, with
effects that are cell type and tissue specific (Coffey et al., 1988;
Pietenpol et al., 1990; Bendelac et al., 1997; Thannickal et al.,
2003; Kronenberg and Rudensky, 2005; Leveen et al., 2005; Marie
et al., 2006; Li et al., 2007; Liu et al., 2008). TGF-β1 is an autocrine
and paracrine signal that can induce fibroblast proliferation
and/or differentiation into myofibroblasts (Figure 1) (Lehnert
and Akhurst, 1988; Turley et al., 1996; Tobin et al., 2002).
Growth factors are necessary for fibroblast proliferation and
TGF-β1 is representative of these growth factors. TGF-β1 is
also able to induce fibroblast to myofibroblast differentiation,
which can be measured by the presence of αSMA in cultured
cells (Figure 1) (Fine and Goldstein, 1987; Desmouliere et al.,
1993; Thannickal et al., 2003). High concentrations of TGF-
β1 have been shown to induce alveolar epithelial cell apoptosis
(Figure 1) (Yanagisawa et al., 1998; Hagimoto et al., 2002;
Kuwano, 2008) and are therefore detrimental to epithelial cell
survival during wound healing. In opposition to TGF-β1, PGE2
is a well characterized anti-fibrotic lipid mediator with a wide
range of influence that is cell and tissue type specific. In
pulmonary tissues, PGE2 is predominantly secreted by epithelial
cells as an inducer of fibroblast quiescence (Lama et al., 2002;
Moore et al., 2003). It also serves as a negative regulator of
TGF-β1, inhibiting fibroblast proliferation and differentiation,
myofibroblast ECM secretion, and TGF-β1 induced epithelial
cell apoptosis (Figure 1) (Fine et al., 1989; Kolodsick et al.,
2003; Moore et al., 2003; Tian and Schiemann, 2010; Epa et al.,
2015). We consider that PGE2 is representative of mediators
that inhibit fibroblast activation. Epithelial cells, fibroblasts,
and myofibroblasts all play important roles in lung function
and pulmonary wound healing (Diegelmann and Evans, 2004;
Strieter, 2008; Crosby and Waters, 2010; Guo and Dipietro,
2010; Camelo et al., 2014). Their interactions and co-regulation
are paramount to understanding the mechanisms underlying
dysregulation of the wound healing process and the development
of fibrosis (Figure 1). Recent work by Epa et al. (2015) shows
that alveolar epithelial cells from healthy lungs are able to inhibit
TGF-β1-induced fibroblast differentiation and secretion of ECM
proteins in a PGE2 dependent manner in vitro (Epa et al., 2015).
Recent systems biology and modeling approaches by our group
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FIGURE 1 | Diagram of the co-regulatory relationship between
fibroblasts, myofibroblasts, and epithelial cells through TGF-β1 and
PGE2 signaling occurring in lung tissue. TGF-β1 is primarily secreted by
fibroblasts but can also be secreted in small part by epithelial cells (Willis and
Borok, 2007). PGE2 is primarily secreted by epithelial cells but can also be
secreted in small part by fibroblasts (Lama et al., 2002; Moore et al., 2003).
TGF-β1 can promote fibroblast proliferation or differentiation into α-smooth
muscle actin positive myofibroblasts, and epithelial cell apoptosis (Desmouliere
et al., 1993; Kolodsick et al., 2003; Thannickal et al., 2003; Epa et al., 2015).
PGE2 can inhibit the actions of TGF-β1 and can also inhibit myofibroblast
secretion of extracellular matrix (ECM) proteins (Fine et al., 1989; Moore et al.,
2003; Thannickal et al., 2003; Thomas et al., 2007; Tian and Schiemann,
2010; Epa et al., 2015). Dashed arrows indicate secretion of a molecule. The
thickness of the arrow indicates relative contribution of the cell type to the
mediator concentration. Solid lines indicate an action of the cytokine on a
given cell type. Arrows indicate a positive effect on the cell while bar headed
lines indicate a negative effect. ECM is the extracellular matrix.
further demonstrate the importance of PGE2 in regulating the
activation of fibroblasts (Warsinske et al., 2015). As observed
in other systems, it is likely that a balance of both positive
and negative regulators (e.g., TGF-β1 and PGE2 respectively)
is necessary for achieving homeostasis and avoiding excessive
fibroblast activation (Cilfone et al., 2013; Warsinske et al., 2015).
PGE2 is also shown to protect epithelial cells from toxicity of
pro-fibrotic mediators like TGF-β1 (Saha et al., 1999). Together
TGF-β1 and PGE2 serve as examples of positive and negative
regulators to preserve balance in the responses of epithelial cells,
fibroblasts, and myofibroblasts to tissue damage (Figure 1).
Treatments for pulmonary fibrosis are limited. Lung
transplantation was considered the only available intervention
until recently. In October of 2015, two drugs, Nintedanib and
Pirfenidone, were approved by the United States Food and
Drug Administration (FDA) for the treatment of IPF (George
et al., 2016). Neither of these available therapies is curative. Both
treatments slowed but did not halt or reverse the progress of
IPF marked by a reduction in the decline of patients forced vital
capacity (FVC) (King et al., 2014; Kreuter, 2014; Lederer et al.,
2015; Richeldi et al., 2015; Costabel et al., 2016).
Both drugs target the dynamics of fibroblasts, namely
inhibiting proliferation, differentiation, and TGF-β1 production.
However, neither nintedanib nor pirfenidone have been
demonstrated to promote the survival or regeneration of
epithelial cells in a fibrotic lung. There is evidence that
pirfenidone may even inhibit retinal epithelial cells (Wang et al.,
2013).
Here we construct an in silico model that captures the co-
regulation of fibroblasts and epithelial cells in vitro. There is
substantial support for constructing agent-based models (ABMs)
of in vitro co-culture systems. These models are used to study
a wide range of processes including, but not limited to wound
healing (Maini et al., 2004; Walker et al., 2004; Mi et al., 2007;
Stern et al., 2012), tissue patterning (Thorne et al., 2007), and
tumor progression (Mansury et al., 2002; An et al., 2009; Zhang
et al., 2009). The construction of this model is based on previous
work in our lab building a 3D model of granuloma formation in
the lung.
With this model, we seek to identify which mechanisms of
co-regulation determine fibroblast and epithelial cell outcomes
during wound healing. By capturing a wide range of possible
outcomes we are able to predict which mechanisms would be
good potential therapeutic targets for preventing and reversing
fibrosis. We hypothesize that a two-hit approach targeting
specific mechanisms to both inhibit fibroblast dysregulation and
simultaneously promote epithelial cell survival is necessary to
halt or reverse damage associated with pulmonary fibrosis. In
order to construct the model and test this hypothesis, we take
a systems biology approach that combines in vitro experiments
with in silico simulations of a co-culture system. We use a multi-
scale, hybrid ABM to identify mechanisms that simultaneously
and independently drive fibroblast dysregulation and epithelial
cell death. We take a reductionist approach to fibrosis, looking
solely at the cells that are experiencing damage (epithelial cells)
or inflicting damage (fibroblasts and myofibroblasts) and model
representative pro- and anti-fibrotic mediators rather than a
more complex tissue environment. This co-culture environment
enables us to focus our search for mechanisms driving outcomes
for these cells while limiting potentially confounding factors. It
also allows us to look specifically at co-regulation of fibroblasts
and epithelial cells and concurrently compare the effects of
intervention strategies. Our model enables us to predict whether
a two-hit synergistic therapeutic strategy for pulmonary fibrosis
addressing multiple aspects of the disease will be the most
successful at improving cellular outcomes.
METHODS
In vitro Studies of Fibroblast Proliferation
The IMR-90 normal human lung fibroblast cell line was obtained
from American Type Culture Collection (ATCC; CCL-186).
Approximately 5000 cells/well are plated onto each well of a 96
well plate and either left untreated, treated with 0.1–4 ng/ml of
activated TGF-β1, or treated with 0.1–100 nM of PGE2. Cells
were treated with 10µCi of radioactive thymidine (Fisher) at 32 h
and harvested at 48 h post treatment. Cells were harvested onto
glass fiber filters using an automated cell harvester and filters
were counted using a beta scintillation counter. Proliferation was
compared by counts per minute (cpm) between samples using
ANOVA with a post-hoc Sidak multiple comparisons test.
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In vitro Studies of Fibroblast Differentiation
Approximately 75,000 IMR-90 cells were plated into 8-well Titer-
tek slides and cultured in SFM for 16 h to synchronize cells
and restore basal levels of αSMA. After 16 h the cells were left
untreated, or treated with 0.1, 0.5, 1.0, 2.0, or 4.0 ng/ml of TGF-
β1 for 24 h. Cells were then blocked with 1% FBS and stained with
a 1:500 fold dilution of anti-αSMA (Sigma F3777) fluorescently-
conjugated antibody. The cell nuclei were stained with DAPI and
coverslips were added using Vectashield (Vector brand) H1200.
Three to five fields per well were counted (at least 300 total
cells) and the proportion of total cells expressing αSMA was
determined.
In vitro Studies of Epithelial Cell Death
Type II alveolar epithelial cells were isolated from wild type
mice per standard protocol (Corti et al., 1996) and then plated
on Matrigel (BD Biosciences) in Small Airways Growth Media
(SAGM) (Lonza) with 5% FBS (Hyclone) and 10 ng/ml KGF
(PeproTech). Twenty-four hours later cells were trypsinized
and replated in serum free SAGM on Matrigel in a 24-well
plate. Seventy thousand cells were plated in each well. Twenty-
four hours later, the cells were treated with TGF-β1 added
at different concentrations as well as IncuCyte Caspase-3/7
Reagent for Apoptosis (Essen BioScience) at 5µM, according
to the manufacturer’s instructions. This reagent is cleaved by
activated caspase-3/7 resulting in nuclear fluorescent staining.
Twenty-four hours later, cells were analyzed under a fluorescent
microscope. The percent of fluorescent cells was manually
counted for each dose of TGF-β1. We had four replicate wells
and counted 2–4 fields per each replicate a total of 8–16 fields for
each dose of TGF-β1.
Multi-Scale Model Construction
Cellular Scale Agent-Based Model
ABMs are a class of in silicomodels that demonstrate how system
level dynamics can emerge as a result of the adaptive behavior of
individuals. They do this by assigning probabilistic actions and
traits to individual agents within a system, and then tracking
these actions over time and space. These models have a defined
domain where agents can interact with each other and their
environment. Agents (cells) are tracked in a discrete fashion (i.e.,
counted) and therefore some ABMs can provide spatial outputs
as well as numerical outputs. Because the behaviors of agents
can be probabilistic, ABMs are stochastic in nature. Our ABM
consists of three cellular agent types: fibroblasts, myofibroblasts,
and epithelial cells. The environment of our ABM simulates an
in vitro cell culture plate representing a cubic area of 1.73×1.73×
6.20mm, or about one tenth the volume of a well in a 96 well plate
(Figure 2). We choose to model one tenth of the well to reduce
the computational burden of the three dimensional (3D) model.
Our simulated plate is partitioned into a grid with side lengths of
81 compartments (81 × 81) and makes up the first layer of our
model. There are 6561 compartments in each layer of the model
and 282 layers in total. The bottom layer represents the surface of
the dish. The 281 layers above the dish make up a large media
compartment that represents the depth of a plate (∼6.2mm).
There are a total of 1,850,202 compartments in the model with
a total volume of ∼19.7µL. The construction of this model is
based on our previous work with ABMs, including unpublished
work with 3Dmodels (Segovia-Juarez et al., 2004; Ray et al., 2009;
Fallahi-Sichani et al., 2011; Cilfone et al., 2013, 2015a; Chang
et al., 2015).
Within this framework, agents follow cell-type-specific rules
capturing physiological interactions tracked at the cellular scale
(Figure 2). Cellular interactions are guided by rules that include
movement of fibroblasts on the surface of the plate, cellular
contact inhibition; myofibroblast cell death, TGF-β1 mediated
epithelial cell death, TGF-β1- and PGE2-mediated fibroblast
proliferation, fibroblast differentiation into myofibroblasts, and
myofibroblast secretion of ECM. For a full list of cellular model
rules, see Supplementary Material. Cells in our simulated culture
dish, like cells in vitro, are adhesion-dependent, meaning that
they adhere to the surface of the plate (Thannickal et al., 2003).
ECM and latent TGF-β1 also adhere to the bottom of the plate
(Shi et al., 2010). The ECM proteins are assumed to be cross-
linked, forming a matrix on the bottom of the plate (Shi et al.,
2010). Latent TGF-β1 adheres to this matrix. When TGF-β1 is
activated, the active molecule is released from the matrix and can
diffuse through the media.
Molecular Scale Ordinary Differential Equation Model
Figure 2 shows a schematic of the molecular scale model.
We use our ordinary differential equation (ODE) model
of fibroblast receptor-ligand dynamics described previously
(Warsinske et al., 2015). Briefly, non-linear ODEs capture
not only TGF-β1 synthesis, degradation, activation, receptor
binding, and dissociation but also receptor dynamics including
synthesis, internalization, recycling, and degradation of the
TGF-β1 receptor complex. The model provides coarse-grained
dynamics for SMAD and Rho/ROCK signaling as well as for
adhesion and PGE2 signaling in fibroblasts. This earlier work
identified the need for both a positive and negative regulator to
achieve homeostatic fibroblast activation. For example, periodic
signaling from either TGF-β1 (an example positive regulator) or
PGE2 (an example negative regulator) was insufficient to produce
controlled fibroblast activation.
Active TGF-β1 and PGE2 are secreted from cells or released
from the ECM into the media compartment where they diffuse in
3D (Cilfone et al., 2015b). Both TGF-β1 and PGE2 can degrade
over time. Extracellularmediator concentrations influence αSMA
synthesis by fibroblasts and myofibroblasts, as detailed in the
molecular model described below. Similarly, αSMA from the
molecular model described below drives fibroblast differentiation
(see list of all rules in Supplementary Material).
Linking Molecular and Cellular Scale Models
We capture both molecular and cellular actions in a multi-
scale hybrid model by linking the cellular scale virtual co-
culture ABM and molecular scale TGF-β1dynamics ODE model
described above using techniques previously described (Fallahi-
Sichani et al., 2011; Cilfone et al., 2013, 2015a,b). In particular,
an output from the molecular level model—αSMA—is a feed
forward input into the cellular level model, driving fibroblast to
myofibroblast differentiation. The concentration of TGF-β1 and
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FIGURE 2 | Schematic representation of both cellular and molecular scale physiological interactions in the hybrid multi-scale computational
co-culture model showing linking of models. The cellular scale model (represented by the grid) contains three cell types; fibroblasts, myofibroblasts, and epithelial
cells. At the cellular scale fibroblasts are capable of probabilistic movement which is inhibited by the presence of other cells (only a single cell can occupy a grid space
at a given time). Epithelial cells and myofibroblasts can undergo TGF-β1 induced death and apoptotic death respectively. Fibroblasts secrete TGF-β1, which diffuses in
3D. Epithelial cells secrete PGE2, which also diffuses in 3D. All cell types respond to chemical concentrations present in their local environment. We coarse-grained
epithelial-cell binding dynamics for both TGF-β1 and PGE2. Fibroblasts and myofibroblasts have coarse-grained binding dynamics for PGE2, and fine grained-binding
dynamics of TGF-β1. The fine grained TGF-β1 binding dynamics are defined by the molecular scale mathematical model that runs within each fibroblast and
myofibroblast agent (shown in red bubble). Within this model active TGF-β1 (yellow hexagon) is bound by the TGFβ1 receptor complex (blue and red) on the surface of
the cell. Bound receptors are internalized and can induce downstream SMAD signaling ultimately inducing the synthesis of αSMA and latent TGF-β1 (yellow and
orange polygon). Following signaling, the internalized TGF-β1 is degraded and the receptor complex is either degraded or restored to the surface of the cell. PGE2
(purple circle) is up-taken by cells and serves as a negative regulator of αSMA and TGF-β1 synthesis. Arrows indicate effects that promote behaviors, while bar
headed lines indicate inhibitory effects. Contents within the red circle depict a previously published molecular scale model of TGF-β1 signaling (Warsinske et al., 2015)
that is operational within all fibroblasts in the model.
PGE2, secreted by fibroblasts and epithelial cells, are outputs of
the cellular scale model and inputs into themolecular scale model
of fibroblast activation. These mediators dictate αSMA synthesis
in the molecular scale model completing the connection between
the two models and scales. Thus, the cellular and molecular
scale models are connected by extracellular levels of TGF-β1 and
PGE2, and intracellular αSMA (Figure 2).
Parameter Derivation and Estimation
Parameter values are identified from published experimental
work, estimated from experiments herein, and/or predicted using
uncertainty analysis. The rate constants for latent and active
TGF-β1 degradation were derived from half-lives published by
Wakefield et al. (9.2 ± 1.4min and 2.7 ± 0.4min respectively)
assuming first order kinetics (Wakefield et al., 1990). Additional
parameters obtained from the literature are as described in
Warsinske et al. (2015).
The threshold concentrations of TGF-β1 and PGE2 that allow
or inhibit fibroblast proliferation in vitro were derived from
experiments herein. Fibroblasts proliferate in concentrations of
TGF-β1 up to 1 ng/ml as compared to fibroblasts cultured in
complete media (CM) alone (Figure 3A). At 2 and 4 ng/ml
fibroblast proliferation is significantly reduced compared to
untreated cells, likely due to myofibroblast differentiation.
Fibroblasts proliferate uninhibited in concentrations of PGE2
up to 1 nM (Figure 3B). At 0.1 nM PGE2 fibroblasts proliferate
significantly more than fibroblasts cultured in CM alone
(Figure 3B). Fibroblast proliferation is significantly inhibited at
10 and 100 nM concentrations of PGE2 (Figure 3B). Fibroblasts
cultured in complete media had a doubling time of ∼24 h (data
not shown).
Parameters estimated using uncertainty analysis (described
below) include soluble PGE2 degradation rate constant, fibroblast
sensitivity to PGE2, probability of fibroblast movement, αSMA
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FIGURE 3 | Estimating fibroblast proliferation thresholds modulated by TGF-β1 and PGE2. (A) IMR90 fibroblasts were cultured in complete media (CM) and
treated with 0.1, 0.5, 1.0, 2.0, or 4.0 ng/ml of TGF-β1 for 48 h in the presence of radioactive thymidine. Proliferation was measured in counts per minute (cpm). Sidak’s
multiple comparison test was used to determine significance (Salkind and Abdi, 2007). Fibroblast proliferation was significantly reduced compared to CM alone in the
presence of 2.0 and 4.0 ng/ml of TGF-β1. (B) IMR90 fibroblasts were cultured in CM alone or with 0.1, 1.0, 10.0, 100.0 nM of PGE2 for 48 h in the presence of
radioactive thymidine. Proliferation was measured in cpm. Sidak’s multiple comparison test was used to determine significance (Salkind and Abdi, 2007). Fibroblast
proliferation was significantly increased compared to CM alone in 0.1 nM PGE2 and significantly decreased in 10 and 100 nM PGE2. There was no difference in
proliferation between fibroblasts cultured in CM and 1 nM PGE2. The significance line without the end irons indicates p > 0.05 for all comparisons under the line.
*p < 0.05 **p < 0.01 ***p < 0.001 ****p < 0.0001.
synthesis rate, max αSMA, and level of TGF-β1 lethal to epithelial
cells.
Cellular-Scale Model Calibration
The cellular scale ABM is calibrated to reflect in vitro
experimental data generated by our group (Figures 4, 5).
Fibroblast differentiation is calibrated to fit in vitro studies of
fibroblast differentiation described above. We assume that the
probability that a fibroblast will differentiate in a given simulation
time step is linearly related to the amount of αSMA synthesized
by the fibroblast:
Probability of differentiation =
slope ∗
amount of αSMA synthesized by the cell
maximum amount of αSMA a cell can synthesize
(1)
where the slope determines the sensitivity of the system to αSMA.
This relationship allows us to calibrate the slope and max αSMA
so that the system reasonably fits experimental data of fibroblast
differentiation (Figure 4). We also assume that the probability
that an epithelial cell will apoptose in a given time step is
proportional to the amount of TGF-β1 it has bound (Figure 5),
and that this relationship is captured by a saturation curve:
Probability of apoptosis =
m ∗
amount of TGF-β1
bound by the cell
amount of TGF-β1 bound by the cell
+
(
k ∗ amount PGE2 bound by the cell
)
+ C
(2)
where m determines the sensitivity of the system to TGF-β1, k
determines the sensitivity of the system to inhibition by PGE2,
and C is a non-zero constant. We calibratem, k, and C so that the
system reasonably fits experimental data.
Initial conditions for the cellular scale virtual co-culture ABM
are chosen to replicate experimental conditions. Five thousand
epithelial cells and 500 fibroblasts are seeded on the surface of
the model plate at time 0, creating a simulation environment
that has ∼84% cellular confluence. One thousand five hundred
simulations (virtual experiments) were performed varying all
parameter values by∼2 orders of magnitude except for the initial
conditions and diffusivities of TGF-β1 and PGE2.
Uncertainty and Sensitivity Analysis
We use uncertainty analysis to quantify how variation in
parameter values leads to variation in model output (Marino
et al., 2008). These variations can occur at the molecular and
cellular scales in the model and can influence outputs spanning
these biological scales. When parameters at one scale influence
outcomes at that scale they are considered to have an intra-
model influence. Intra-model influences can occur within either
the molecular or cellular scale models. When mechanisms at
one scale effect outcomes at the other scale these parameters are
said to have inter-model influence. Uncertainty analysis allows
us to observe model outcomes based on a wide value range
for each parameter value. We vary numerous parameters in
the model over a wide range (two orders of magnitude) and
compare how these variations affect model outputs. Sensitivity
analyses enable us to identify which model parameters have a
significant influence and the extent of that influence on a given
model output (Marino et al., 2008; Warsinske et al., 2015). Partial
rank correlation coefficients (PRCCs) are used to determine
the sensitivity of an output to a given parameter. PRCC values
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FIGURE 4 | Comparison between data and computational model fit for
fibroblast differentiation at 24h in response to TGF-β1 treatment.
IMR90 fibroblasts were cultured in serum free media (SFM) alone or with an
additional 0.1, 0.5, 1.0, 2.0, 4.0 ng/ml acid activated TGF-β1. The proportion
of differentiated cells at 24 h was determined by staining with anti-αSMA and
DAPI. (A) Representative image of fibroblasts cultured in SFM alone at 100x
magnification. (B) Representative image of fibroblasts cultured in 4.0 ng/ml
TGF-β1 at 100x magnification. (C) Representative images of fibroblasts
cultured in SFM alone at 400x magnification. (D) Representative images of
fibroblasts cultured in 4.0 ng/ml TGF-β1 at 400x magnification. (E) Open gray
triangles indicate experimental results. Solid black squares indicate simulation
output. The proportion of either experimental or simulated fibroblasts having
undergone differentiation at 24 h is compared to the initial concentration of
active TGF-β1 in the tissue culture or simulation. The simulation data closely
matches the experimental data.
describe the correlation between the parameter value and the
output in a range from−1 to+1. PRCC values are differentiated
using a student t-test of significance. In this work we use the
LHS algorithm to generate 500 unique parameter sets, and run
each set in triplicate (Marino et al., 2008). PRCC values are
considered significant and with a p < 0.01. We evaluate our
model simulations (defined below) at day 7 because this time-
point reflects the full range of possible model outcomes.
Multi-Scale Model Simulation
Our hybrid multi-scale model links both the molecular and
cellular scale models, described previously. The combinedmodel,
resulting from the linking of the two models (see Linking
molecular and cellular scale models above) allows us to simulate
biological events with molecular and cellular scale details over
time. Simulations are defined as an iteration of the multi-scale
model that is run on the computer over a defined period of
time. Simulations include a set of initial conditions, model rules,
equations, and parameter values (see Supplementary Material for
complete description of parameters and rules).
Model simulations can be evaluated by comparing individual
outputs or the combined overall outcome of the simulation.
Initial conditions include the number of each cell type, the
concentrations of TGF-β1 and PGE2 in the environment, and the
number of TGF-β1 receptors present on each fibroblast at time
0. In our model we track number of epithelial cells, fibroblasts,
and myofibroblasts over time and position in the environment.
Model outputs consist of not only these numbers in space and
time but also concentrations of PGE2 and TGF-β1. A model
outcome differs from a model output in that it encompasses
multiple outputs and evaluates them over the entire timespan
of the simulation. An example of a model outcome would
be “Rapid epithelial cell death with fibroblast proliferation and
differentiation” where outputs for all cell types are considered.
RESULTS
TGF-β1 and PGE2 Modulate Fibroblast
Proliferation In vitro in a Dose Dependent
Manner
Previous work has demonstrated the roles of TGF-β1 and PGE2
in fibroblast to myofibroblast differentiation (Kolodsick et al.,
2003; Thannickal et al., 2003; Epa et al., 2015; Warsinske et al.,
2015). We sought to determine the capacity for TGF-β1 and
PGE2 to influence IMR-90 fibroblast proliferation in vitro. We
first compared levels of radioactive thymidine incorporation after
48 h in IMR-90 cultures with complete media (CM) or CM and
the addition of 0.1–4.0 ng/ml acid activated TGF-β1 (Figure 3A).
Data show no increase in proliferation and no decrease in
proliferation in fibroblasts treated with 0.1, 0.5, or 1.0 ng of
acid activated TGF-β1. A significant decrease in proliferation
in 2.0 or 4.0 ng of TGF-β1 indicates decreased proliferation
under these conditions (Figure 3A). We next compared levels
of radioactive thymidine incorporation after 48 h of culture
in CM alone, or CM and 0.1–100 nM of exogenous PGE2
(Figure 3B). Data show increased proliferation of fibroblasts in
0.1 nM PGE2. Fibroblasts cultured in CM with 1.0 nM PGE2
showed no change in proliferation. Data also show that 10 or
100 nM concentrations of PGE2 induced a significant decrease in
proliferation (Figure 3B).
TGF-β1 Mediates Fibroblast Differentiation
and Epithelial Cell Death In vitro in a Dose
Dependent Manner That Is Captured by the
Multi-Scale Model
TGF-β1 has been demonstrated to induce fibroblast
differentiation (Desmouliere et al., 1993; Kolodsick et al.,
2003; Thannickal et al., 2003; Thomas et al., 2007; Epa et al.,
2015). αSMA expression is a marker of fibroblast differentiation
(Hinz et al., 2007). We sought to determine the ability of TGF-β1
to induce fibroblast differentiation by determining how an
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FIGURE 5 | Comparison between data and computational model fit for epithelial cell survival at 24h in response to TGF-β1 treatment. Type II alveolar
epithelial cells were cultured in SFM alone or with an additional 0.5, 1.0, 2.0, 4.0 ng/ml acid activated TGF-β1. The number of caspase 3 positive cells was evaluated
at 24 h by fluorescent staining. (A) Representative image of cell cultures treated with 0.0, 0.5, 1.0, 2.0, or 4.0 ng/ml of TGF-β1 at 200x magnification. These images
show an increase in caspase 3 activation of the epithelial cells in the presence of increasing concentrations of TGF-β1. (B) Open gray triangles indicate experimental
results. Solid black squares indicate simulation output. We compare the proportion of experimental or simulated epithelial cells having undergone apoptosis at 24 h to
the initial concentration of active TGF-β1 in the cell culture or computer simulated model. The simulation output closely matches the experimental outputs.
initial dose of TGF-β1 affects the proportion of differentiated
fibroblasts at 24 h. We cultured fibroblasts in serum free media
(SFM) alone, or SFM plus initial concentration of 0.1, 0.5, 1.0,
2.0, and 4.0 ng/ml exogenous acid-activated TGF-β1 for 24 h
and counted the number of αSMA positive cells compared to
the total number of cells present in high powered microscope
fields (Figure 4). Data show a positive dose response between
the concentration of initial active TGF-β1 and the proportion of
activated fibroblasts at 24 h.
To capture this fibroblast dynamic in our computational
model, we used Equation (1) to express the relationship between
αSMA synthesis and fibroblast differentiation. We performed
1500 simulations each with 5000 fibroblasts and an initial
concentration of 0.0–5.0 ng/ml exogenous acid-activated TGF-
β1. After a simulated time of 24 h, we calculated the percent
of αSMA positive cells in the total cell population (Figure 4).
Our model captures the biology of fibroblast differentiation by
recapitulating the dose response observed in the experimental
dataset.
We sought to identify the correlation between TGF-β1 and
epithelial cell death by determining how an initial dose of
TGF-β1 affects the percentage of caspase positive epithelial
cells at 24 h. TGF-β1 has been demonstrated to induce
epithelial cell apoptosis (Bohm et al., 2014; Crosas-Molist and
Fabregat, 2015) and caspase activation is a marker of apoptosis
(Budihardjo et al., 1999). We cultured type II alveolar epithelial
cells in SFM or SFM plus an initial concentration of 0.5,
1.0, 2.0, and 4.0 ng/ml exogenous acid-activated TGF-β1. At
24 h, we calculated the percentage of caspase positive cells
in high-powered microscope fields (Figure 5). Data show a
positive dose response between the concentration of initial
active TGF-β1 and the proportion of apoptotic epithelial cells
at 24 h.
To capture epithelial cell dynamics in our computational
model, we used Equation (2) to express the relationship
between TGF-β1 and epithelial cell apoptosis. We
performed 1500 simulations each with 5000 epithelial
cells and an initial concentration of 0.0–4.0 ng/ml
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exogenous acid-activated TGF-β1. After a simulated
time of 24 h, we calculated the percent of the total
population of dead epithelial cells. Our model captures
the biology of epithelial cell apoptosis by recapitulating
the dose response observed in the experimental dataset
(Figure 5).
Multi-Scale Model Captures a Wide Range
of Possible Fibroblast, Myofibroblast, and
Epithelial Cell Outcomes in a Virtual
Co-culture Environment
We next tested whether our computational model can
capture the range of possible biological co-culture outcomes
observed experimentally. We explored outcomes for a range
of physiologically plausible parameter values derived from
literature, our work, or estimated using uncertainty analysis
(Tables S1–S4); varying parameter values allows us to manipulate
the relative importance of particular mechanisms in the model.
Multi-scale model outcomes fell primarily into four categories
that we classify as: healthy tissue outcome, rapid epithelial cell
death with fibroblast proliferation and differentiation, gradual
epithelial cell death with fibroblast proliferation, and early
epithelial cell death with excessive fibroblast proliferation and
differentiation. Representative simulations at the end of 7
days illustrate model outcomes (Figure 5). We have selected
four outcomes that are representative of common trends
identified in our LHS. Outcomes falling into each category
share some parameter trends. These trends are described in
the figure legend with specific values given for the simulation
shown (see Supplementary Material Tables S1–S4 for full
parameter ranges). Our first outcome category, a healthy tissue
outcome, shows that under idealized conditions epithelial
cells survive and fibroblasts remain quiescent (Figure 6A).
By the end of 7 days fibroblasts had not proliferated and
the epithelial cells survived. Our second outcome category,
rapid epithelial cell death with fibroblast proliferation and
differentiation, shows that under some conditions epithelial
cells undergo rapid apoptosis (Figure 6B); ∼50% of the
epithelial cells died in the first 24 h. Fibroblast proliferation
occurs during the first 24 h. Fibroblast to myofibroblast
differentiation begins very early in the simulation. By 24 h
all fibroblasts have differentiated restricting proliferation and
resulting in fewer cells overall. In the third outcome category,
gradual epithelial cell death with fibroblast proliferation,
fibroblasts undergo a large amount of proliferation more
than doubling in the first 48 h of the simulation (Figure 6C).
In this simulation epithelial cells experience gradual cell
death, and by 168 h nearly half of the epithelial cells have
died. Our fourth outcome category, excessive fibroblast
proliferation, and differentiation, shows nearly complete
epithelial cell death by 168 h (Figure 6D). In this simulation
fibroblasts proliferate rapidly doubling by 48 h. At this time
some fibroblasts begin to undergo differentiation while others
continue to proliferate. After 168 h all of the fibroblasts
have differentiated so that the entire plate is covered with
myofibroblasts (Figure 6D).
Analysis of the Multi-Scale Model Reveals
Key Mechanisms Driving Fibroblast
Proliferation, Differentiation, and Epithelial
Cell Survival in a Co-culture Environment
A wide range of possible multi-scale model simulation outcomes
for fibroblast proliferation, differentiation, and epithelial cell
survival can be achieved by manipulating mechanisms of
fibroblast and epithelial cell co-regulation (Figure 6). To
determine which mechanisms and to what extent they are
responsible for driving these different outcomes, we performed
sensitivity analysis on the outputs from 1500 simulations of our
multi-scale model at day 7 as described in Methods. The analysis
predicts mechanisms dictating fibroblast proliferation without
differentiation (determined by fibroblast number) (Table 1A). Of
the mechanisms found to drive fibroblast proliferation, PGE2
synthesis had the strongest influence (p < 0.01). The analysis
predicts which mechanisms dictate myofibroblast differentiation
(determined by number of myofibroblasts) (Table 1B). Of these
mechanisms, TGF-β1 synthesis and PGE2 inhibition of TGF-β1-
induced differentiation had the strongest effect on myofibroblast
number (p < 0.01). PRCC analysis predicts that the strongest
mechanisms driving epithelial cell survival (determined by
epithelial cell number) (Table 1C) are predominantly different
frommechanisms driving fibroblast proliferation (Table 1A) and
differentiation (Table 1B). Of the mechanisms found to drive
epithelial cell survival; TGF-β1 synthesis and TGF-β1 activation
had the strongest effect on epithelial cell number (p < 0.01).
These mechanisms may be strong candidates for therapeutic
intervention.
Multi-Target Intervention Strategies
Promote Healthy Tissue Repair Better than
Single Target Strategies
From our sensitivity analysis, we established a list of the primary
mechanisms driving fibroblast, myofibroblast, and epithelial
cell outcomes (Table 1). Some of these mechanisms reiterate
previous understandings about fibrosis, and others provide
new insight. Current therapies for pulmonary fibrosis target
TGF-β1 signaling in order to prevent fibroblast dysregulation
(King et al., 2014; Xaubet et al., 2014; Myllarniemi and
Kaarteenaho, 2015). Our analysis identifies that inhibiting TGF-
β1 receptor/ligand complex internalization, the first step in TGF-
β1 signaling, results in an overall decrease in myofibroblast
number (Table 1B). In vitro studies show that high levels of PGE2
inhibit fibroblast proliferation (Figure 3). Our sensitivity analysis
further emphasizes this relationship by highlighting the strong
negative correlation between fibroblast number and epithelial cell
synthesis of PGE2 (Table 1A).
To predict the success of potential therapeutic strategies,
we simulated therapeutic interventions by either promoting or
inhibiting themechanisms identified by our sensitivity analysis as
the most significant for driving fibroblast proliferation, fibroblast
differentiation, and epithelial cell survival. We simulated these
therapeutic strategies in the three outcome categories identified
as rapid epithelial cell death with fibroblast differentiation,
gradual epithelial cell death with fibroblast proliferation and
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FIGURE 6 | Four distinct classes of multi-scale model simulation outcomes varying parameter values. (A) Healthy tissue outcome. Complete epithelial cell
survival can be achieved by baseline parameter values in the model. (B) Rapid epithelial cell death with fibroblast proliferation and differentiation. Parameter
combinations leading to rapid epithelial cell death and early fibroblast differentiation include high TGF-β1 synthesis (k
TGFβ1lat
syn = 1.07× 10
−16). (C) Gradual epithelial
cell death with fibroblast proliferation. Parameter combinations leading to gradual epithelial cell death include low PGE2 synthesis (VePGE2 = 3.16× 10
−27) and low
TGF-β1 proliferation threshold (minprolifTGFβ1 = 1.15× 10
−25). (D) Excessive fibroblast proliferation and differentiation. Parameter combinations leading to excessive
fibroblast proliferation include high TGF-β1 synthesis (k
TGFβ1lat
syn = 9.86× 10
−19), high myofibroblast TGF-β1 binding (konM = 0.001, and decreased PGE2 synthesis
VePGE2 = 1.69× 10
−29). For complete parameter ranges please see Supplementary Material Tables S1–S4. For full length time-lapse simulations please see http://
malthus.micro.med.umich.edu/lab/movies/Co-culture/.
differentiation, and excessive fibroblast proliferation and
differentiation (Figure 7). We first tested single intervention
strategies intended to either inhibit fibroblast proliferation
or differentiation, or to promote epithelial cell survival for
each outcome category. We then took a two-hit approach
and combined treatment strategies that inhibit fibroblast
proliferation or differentiation together with strategies that
promote epithelial cell survival. Thus, for each case we tested
two interventions independently (Figure 7 top) and then in
combination (Figure 7 bottom).
For the outcome category rapid epithelial cell death with
fibroblast differentiation (Figure 7A), we virtually reduced
fibroblast synthesis of TGF-β1 or we increased epithelial cell
synthesis of PGE2. Decreasing TGF-β1 synthesis alone inhibits
fibroblast to myofibroblast differentiation and rescues the
epithelial cells at 168 h but due to the presence of low levels
of TGF-β1 fibroblast proliferation is not inhibited. Increased
synthesis of PGE2 inhibited fibroblast proliferation but did
not decrease the rate of epithelial cell death (Figure 7A
top). Simultaneously decreasing TGF-β1 synthesis together and
increasing PGE2 synthesis inhibited fibroblast to myofibroblast
differentiation and also restored epithelial cell survival by day 7
(Figure 7A bottom).
For the outcome category, gradual epithelial cell death
with fibroblast proliferation (Figure 7B), we virtually reduced
fibroblast synthesis of TGF-β1 or we increased the rate
of PGE2 synthesis by epithelial cells. Reducing TGF-β1
synthesis alone rescues the epithelial cells at 168 h but it
does not inhibit fibroblast proliferation. Increasing PGE2
synthesis inhibited fibroblast to myofibroblast differentiation
and fibroblast proliferation. Increased PGE2 synthesis improved
epithelial cell survival by day 7 but not to the same level as
decreasing TGF-β1 synthesis (Figure 7B top). Combining these
effects both inhibited fibroblast proliferation and differentiation
while fully restoring epithelial cell survival by day 7 (Figure 7B
bottom).
Finally, for the outcome category, excessive fibroblast
proliferation, and differentiation, we virtually reduced TGF-β1
synthesis or reduced TGF-β1 activation. Reducing TGF-
β1 synthesis alone inhibited fibroblast to myofibroblast
differentiation and made a dramatic improvement in epithelial
cell survival at day 7, but did not inhibit fibroblast proliferation.
Decreasing TGF-β1 activation had almost no effect on epithelial
cell survival, strongly inhibited fibroblast differentiation, but
showed no ability to inhibit fibroblast proliferation (Figure 7C
top). However, combining these effects restored epithelial cell
survival by day 7 while inhibiting fibroblast proliferation and
differentiation (Figure 7C bottom). A conclusion from the model
is that different mechanisms must be targeted simultaneously to
affect outcomes of epithelial cell survival, fibroblast proliferation,
and myofibroblast differentiation.
DISCUSSION
Pulmonary fibrosis results from dysregulation of the wound
healing process in the lungs. Epithelial cells, fibroblasts, and
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FIGURE 7 | Virtual individual and combined treatment outcomes for three case studies (compare to B,C,D from Figure 6). Green line represents epithelial
cells, red line represents fibroblasts and yellow line represents myofibroblasts. (A) Rapid epithelial cell death and recovery. The top panel depicts untreated simulation
(solid line) decreased TGF-β1 synthesis (dashed line) or increased PGE2 synthesis (dotted line) in isolation. Decreased TGF-β1 synthesis preserves epithelial cell
number but does not inhibit fibroblast proliferation. Increased PGE2 synthesis inhibits excessive fibroblast proliferation but does not rescue epithelial cell number. The
bottom panel depicts untreated simulation (solid line) and decreased TGF-β1 synthesis in combination with increased PGE2 synthesis (dot-dashed line). Combined
treatment restricts fibroblast proliferation and preserves epithelial cell survival. (B) Gradual Epithelial cell death and recovery. The top panel depicts untreated
simulation (solid line) decreased TGF-β1 synthesis (dashed line) or increased PGE2 synthesis (dotted line) in isolation. Decreased TGF-β1 synthesis preserves epithelial
cell number but does not inhibit fibroblast proliferation. Increased PGE2 synthesis inhibits excessive fibroblast proliferation but results in more rapid decline in epithelial
cell number. The bottom panel depicts untreated simulation (solid line) and decreased TGF-β1 synthesis in combination with increased PGE2 synthesis (dot-dashed
line). Combined treatment restricts fibroblast proliferation and preserves epithelial cell survival. (C) Excessive fibroblast proliferation and recovery. The top panel
depicts untreated simulation (solid line) decreased TGF-β1 synthesis (dashed line) or decreased TGF-β1 activation (dotted line) in isolation. Decreased TGF-β1
synthesis increases but does not preserve epithelial cell number and does not inhibit fibroblast proliferation. Decreased TGF–β1 activation does not inhibit excessive
fibroblast proliferation or rescue epithelial cell number The bottom panel depicts untreated simulation (solid line) and decreased TGF-β1 synthesis in combination with
or decreased TGF-β1 activation (dot-dashed line). Combined treatment restricts fibroblast proliferation and preserves epithelial cell survival.
myofibroblasts each play key roles in tissue regeneration
after injury. The actions of these different cell types are
regulated by pro- and anti-fibrotic cytokines such as
TGF-β1 and PGE2 respectively. During fibrosis, excessive
fibroblast proliferation/accumulation and differentiation into
myofibroblasts paired with epithelial cell death results in thick,
stiff, and scarred lung tissue that is not suitable for breathing
and gas exchange. Our analysis allowed us to identify key
mechanisms driving fibroblast/myofibroblast dysregulation and
epithelial cell death. With this analysis we can predict potential
therapeutic targets and strategies for the treatment of pulmonary
fibrosis.
The use of in silico methods in tandem with experimental
approaches allows us to identify relationships between specific
mechanisms contributing to fibroblast and epithelial cell co-
regulation and their outcomes such as epithelial cell survival and
fibroblast proliferation and differentiation during fibrosis. Our
multi-scale, hybrid ABM is a tool that simulates a computation
platform similar to an in vitro co-culture system. To ensure
that our model accurately reflects biology we used data from
the literature or generated it herein to calibrate it. We take a
reductionist approach to understanding fibroblast differentiation
and epithelial cell regulation and do not capture the full
complexity of the lung environment. Nevertheless, like an
in vitro culture system, our model allows us to test specific
mechanisms involved in fibroblast/epithelial cell co-regulation.
With this unique tool we can evaluate all parts of the co-
regulatory system simultaneously at multiple biological scales
over time. Within our multi-scale model simulations we can
vary rates and magnitudes of cellular and chemical interactions
across a wide range, simulating the effects of thousands of
theoretical intervention strategies. The information produced by
these simulations includes cell number, local and total chemical
concentrations, numbers of proliferation or apoptosis events
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TABLE 1 | Primary mechanisms driving fibroblast, myofibroblast, and epithelial cell numbers.
(A) Significant PRCC values for fibroblast number at day 7 (p < 0.01)
TGF-β1 synthesis PGE2 binding rate Fibroblast sensitivity to
PGE2
Fibroblast insensitivity to
TGF-β1
TGF-β1 proliferation
threshold
PGE2 proliferation
maximum
−0.11 −0.17 −0.12 0.12 −0.11 0.14
Probability of fibroblast movement αSMA
differentiation
maximum
TGF-β1 to PGE2
differentiation threshold
PGE2 synthesis Epithelial cell sensitivity
to PGE2
−0.08 0.07 0.19 −0.40 0.07
(B) Significant PRCC values for myofibroblast number at day 7 (p < 0.01)
TGF-β1 activation TGF-β1 synthesis Fibroblast insensitivity to
TGF-β1
PGE2 inhibition of TGF-β1
induced differentiation
PGE2 synthesis Epithelial cell TGF-β1
binding rate
0.10 0.54 −0.13 −0.26 −0.14 −0.09
(C) Significant PRCC values for epithelial cell number at day 7 (p < 0.01)
TGF-β1 receptor dissociation TGF-β1 synthesis TGF-β1 activation PGE2 binding rate Fibroblast insensitivity
to TGF-β1
αSMA differentiation
maximum
−0.10 −0.79 −0.47 0.11 −0.14 −0.09
TABLE 2 | Potential therapeutics for key mechanisms of fibrosis.
Mechanism Influence on
cell number
Therapeutic References Influence on mechanism
FIBROBLASTS
TGF-β1 synthesis ↑ Pirfenidone Dosanjh et al., 2002 ↓
PGE2 synthesis ↓ IL-1α, TNFα, AA, IL-13 receptor
antagonist
Chen et al., 1995; Hashimoto et al., 2001;
Kraft et al., 2001; Saito et al., 2003
↑
PGE2 binding ↓ CP-533536 Li et al., 2003 ↑
PGE2 sensitivity ↓ Forskolin ↑
Proliferation ↑ Nintedanib, IL-13 receptor
antagonist (QAX 576)
Hashimoto et al., 2001; Kraft et al., 2001;
Saito et al., 2003; Loomis-King et al.,
2013; Myllarniemi and Kaarteenaho, 2015
↓
EPITHELIAL CELLS
TGF-β1 synthesis ↓ Pirfenidone Dosanjh et al., 2002 ↓
TGF-β1 activation ↓ anti-αVβ6 Puthawala et al., 2008 ↓
TGF-β1 sensitivity ↓ TGF-β1 receptor fusion, TGF-β1
receptor antagonist (A8301)
Muraoka et al., 2002; Prasanphanich
et al., 2014; Overgaard et al., 2015
↓
↑ Indicates promotes cell number or mechanism, ↓ Indicates restricts cell number or mechanism.
within a given time frame, and many other details about the
simulated cells and environment. Analysis of these simulated
outputs allows us to determine which potential interventions or
combinations of interventions promote epithelial cell survival
and inhibit dysregulation of fibroblasts and myofibroblasts.
Our simulations yield four major categories of outcomes
characterized by the number of cells left in each cell class after
7 days. We describe these common cases as healthy tissue
outcome, rapid epithelial cell death with fibroblast proliferation
and differentiation, gradual epithelial cell death with fibroblast
proliferation, and excessive fibroblast proliferation and
differentiation. It should be clear that there is a wide range
of outcomes in between these four classes, as cell behavior
in our model and in reality is not discrete but a continuous
range of possibilities. Our results hold nonetheless. Through
uncertainty and sensitivity analysis, we identify mechanisms
driving fibroblast, myofibroblast, and epithelial cell outcomes
defined by cell numbers at 7 days. Although several mechanisms
have a significant impact on fibroblast cell number, the strongest
regulator is PGE2 synthesis by epithelial cells. For myofibroblasts,
TGF-β1 synthesis and the ratio of TGF-β1 to PGE2 permissive
for differentiation are the key mechanisms driving cell number.
Epithelial cell outcome is most dependent on TGF-β1 synthesis
and TGF-β1 activation. It is important to note that fibroblast,
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myofibroblast and epithelial cell survival outcomes are largely
affected by different mechanisms. This implies that treatment
strategies intended to reduce or reverse tissue damage associated
with fibrosis need to target multiple mechanisms specific to
different cell types.
Further exploration of this “two-hit” therapeutic approach
emphasizes the efficacy of combinatorial treatment strategies
over single target strategies. We performed rescue experiments
on the three previously identified poor model outcome
categories. We reduced the synthesis of TGF-β1, increased the
synthesis of PGE2, and or decreased TGF-β1 activation in these
cases and found that in each case, a two-hit treatment strategy
was more effective than a single target approach. In most cases,
one intervention targeted epithelial cells and the other targeted
fibroblasts and/or myofibroblasts. In some cases there were
overlapping effects on multiple cell types, but in all cases a
minimum of two strategies were required for a complete rescue
effect.
As previously described, there are only two therapeutics
available for the treatment of pulmonary fibrosis in the United
States; Nintedanib and Pirfenidone. Independently these drugs
each target one aspect of fibrotic dysregulation. Combined they
could potentially have a synergistic effect. While it is interesting
to speculate on the biologic usefulness of this approach, currently
the costs associated specifically with Pirfenidone and Nintedanib
would be prohibitive for most patients. However, our model
predicts that therapeutic strategies addressing multiple aspects
of fibrotic disease are essential for the effective treatment of
pulmonary fibrosis, and previous analyses have suggested that
single therapeutic strategies are insufficient (Kendall and Feghali-
Bostwick, 2014). We must identify combined therapeutics
strategies that are not cost prohibitive to improve the prognosis
of pulmonary fibrosis patients.
Other existing therapeutic strategies that could be considered
for a more cost effective combined treatments include, but are
not limited to, TGF-β1 receptor fusion proteins (Muraoka et al.,
2002), recombinant human IL-1α and/or TNFα, arachidonic acid
(Chen et al., 1995), and IL-13 receptor inhibitors (Hashimoto
et al., 2001; Kraft et al., 2001; Saito et al., 2003) (Table 2). When
considering inhibition of TGF-β1 signaling as a therapeutic, one
must be cautious of the fact that TGF-β1 is a potent regulator of
autoimmunity (Letterio and Roberts, 1998) and global inhibition
of TGF-β1 receptor signaling could result in the development
of profound immune activation and systemic autoimmunity.
Thus, localized delivery to the lung and perhaps more targeted
approaches to block downstream mediators may show better
efficacy overall (Cilfone et al., 2015c).
Recombinant human IL-1α and recombinant human
TNFα have been shown to stimulate PGE2 synthesis by
endometrial cells via the up regulation of the rate-limiting
cyclooxygenase-2 (COX-2) enzyme important for conversion
of arachindonic acid to PGH2 (Chen et al., 1995) and
ultimately PGE2. By mimicking PGE2 binding, a mechanism
highlighted by our sensitivity analysis, cAMP analogs could
limit fibroblast activation, and also promote epithelial cell
survival. One of the challenges with PGE2-based therapeutics
are that lipid mediators have short half-lives in vivo, and
systemic delivery of PGE2 could result in hemodynamic
complications due to signaling via other EP receptors in
multiple cell types (Audoly et al., 1999; Sugimoto and Narumiya,
2007).
IL-13 has been show to promote fibroblast proliferation and
increase αSMA synthesis, ultimately leading to differentiation
(Hashimoto et al., 2001; Kraft et al., 2001; Saito et al., 2003).
Reduction of IL-13 signaling in fibroblasts through receptor
inhibitors such as QAX 576 (Novartis) (Loomis-King et al., 2013)
could reduce fibroblast cell number, differentiation, and tissue
remodeling functions. It has also been hypothesized that IL-13
may reduce PGE2 production (Saito et al., 2003). Thus, inhibition
of IL-13 receptor signaling may have a dual effect of decreasing
fibroblast proliferation and increasing PGE2 synthesis.
In simulated combinations targeting fibroblasts and
promoting epithelial cells, these therapeutics and others have
the potential to provide synergistic improvements in outcomes
over individual treatment strategies (Table 2). Fibroblasts,
myofibroblasts, and epithelial cells have distinct regulatory
mechanisms during wound healing. The dysregulation of any or
all of these processes requires a multifaceted approach for the full
restoration of tissue integrity. Addressing epithelial cell survival
in conjunction with solving fibroblast dysregulation using either
new or already available therapeutics is the necessary next step to
providing therapy for pulmonary fibrosis.
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